Framycetin 0.5% eye drops
A component of neomycin that is produced by Streptomyces fradiae.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Framycetin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Framycetin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Randomised trials: 3 · Trials: 1 · 1958–2025
Showing the 50 most relevant studies, sorted by most relevant.
Shahid Ahmed, Tahir Masood Ahmed, Abdul Qadeer, et al.
Indus Journal of Bioscience Research, 2025
Background: Wound healing at the split-thickness skin graft (STSG) donor site is an important aspect of reconstructive surgery that has been characterized by pain, delayed healing, and complications. Improving patient outcomes is the ultimate goal, and it is critical and possible to do all that is needed to optimize donor site management. Objectives: Experimental objectives to determine the effectiveness of Betamethasone + Polymyxin B dressing to that of sterile tulle dressing soaked in 1% framycetin sulfate in enhancing donor site healing and minimizing complications. Materials and Methods: A prospective randomized controlled trial was carried out for 12 months at CMH Rawalpindi, Pakistan in the duration from 1st November 2023 to 30th November 2024. Out of 100 patients, both groups were formed, and the donor sites were treated with the dressing. Recovery period, reported pain, and adverse outcomes were assessed at 2-week, 4-week, and 6-week intervals. Results: The beta-methadone and polymyxin B dressing was found to have reduced the length of healing time (12 ± 2.5) as compared to framycetin sulfate dressing (16 ± 3.2) p<0.05 for pain scores and infection rates. Other post-operative-related complications that were lowered included scarring and hyper granulation. Conclusion: Betamethasone + Polymyxin B dressing is more effective in managing the donor site of STSG, has lesser healing time, and less pain and complications.
Abstract licence: CC BY 4.0
Medhi Denisa Alinda, Paulus Mario Christopher, Muhammad Yulianto Listiawan, et al.
Indian Journal of Dermatology, Venereology and Leprology, 2022
- Mesenchymal Stem Cells
- Leprosy
- Foot Ulcer
A. Leach, Y. Wood, Edna Gadil, et al.
The Pediatric Infectious Disease Journal, 2008
Zhuo Wu, I. Yaqoob, Mehreen Afzal, et al.
PLOS One, 2025
- Hydrogels
- Anti-Bacterial Agents
- Bandages
Background Hydrogels loaded with antibiotics can be an effective drug delivery systemfor treating skin diseases or conditions such asinburns and wound healing. Objectives The current research work was planned to preparea hydrogel dressing for an effective wound healing. The hydrogel formulation was aimed to provide sustained drug release, reducing the frequency of repeated applying the transdermal drug formulation or patch. Methods Different polymers, polyvinyl alcohol, sodium alginate, and polyvinyl pyrrolidonein varying ratios were used to prepare hydrogels by freeze-thawing method. The prepared hydrogel formulations were loaded with framycetinsulphate (FC-S), a topical aminoglycoside. Results Swelling behaviour, drug release pattern, wereinvestigated.Equilibrium and dynamic studies were conducted at pH 7.4. The prepared hydrogel formulations showed Euilibriumswellingratio of 197.5%. The in-vitro release pattern of FC-Shydrogels was determined by dissolution testing. The prepared hydrogels were characterized by scanning electron microscopy (SEM)andfourier transform infrared (FTIR)spectroscopy.Animal study was conducted on rats to evaluatethe in-vivo therapeutic effectiveness of FC-S hydrogels in wound healing. For that purpose,wounds were induced in the animals. The drug loaded hydrogel dressing was effiecent in wound heaing as the wound treated with FC-S loaded hydrogel was almost completely healed (97%) on the fifth day in comparison to commercially available product (Sofra Tulle gauze) that healed 86%, whereas free FC-S manifested healing at 76%. Conclusion It was observed that hydrogel dressing loaded with FC-S was therapeutically more efficient and can be used as a potential candidate for wound healing.
Abstract licence: CC BY 4.0
Vasyl I. Popovych, Ivana V. Koshel
Archives of Microbiology & Immunology, 2023
Satkar Prasad, Shyam Bahadur, S. Ghatuary
International Journal of Innovations in Science Engineering And Management, 2025
The present study evaluates the effectiveness of the ethanolic extract of Nymphaea alba in wound healing and administers phytochemicals using "an excision and incision wound model on Wistar strain albino rats". Plant extracts have a higher phytoconstituent concentration, according to “phytochemical screening”. "Phenolic compounds, alkaloids, carbohydrates, flavonides, glycosides, and tannin" were all detected in the ethanolic extract of Nymphaea alba. "The tensile strength of the healed wounds" was assessed using the incision wound model, and the influence of wound healing was assessed using the excision wound model, which took into consideration the epithelialisation time and the percentage of wound closure. Wistar albino rats' dorsal surfaces were subjected to excision and incision wounds. Four groups of six rats each were randomly selected from among them. Group I served as the control group, receiving no treatment other than a basic ointment. Group II was used with framycetin sulphate cream (Soframycin, Aventis) and was regarded as the standard group. Group III was given EENA 2% (w/w), while Group IV was given EENA 5% (w/w). These were considered test groups. Compared to the usual control group, Nymphaea alba significantly rises the percentage of wound contraction, reduces its duration of epithelialisation, and increases the tensile strength of the skin in all forms. In view of the positive results, it may be feasible to conduct additional research to evaluate the efficacy of various wound models.
Abstract licence: CC BY-SA
T. Adamovich
Vestnik Farmacii, 2024
In this study antibacterial activity assessment of extraction from the herb Echinacea purpurea, solutions of caffeic and chlorogenic acids (representatives of hydroxycinnamic acids), tea tree, eucalyptus, lavender and sage essential oils, and antimicrobial preparations administered intranasally (sodium sulfacetamide, framycetin sulfate, protargol, neomycin sulfate with polymyxin B sulfate) in relation to one of the causative agents of bacterial infectious rhinitis Staphylococcus aureus was evaluated. Bacteriostatic activity was evaluated by sequential dilution in liquid nutrient medium using an indicator of the metabolic cells activity - triphenyltetrazolium chloride, and bactericidal activity was evaluated by subsequent re-sowing on dense nutrient medium and counting of colony-forming units. Sodium sulfacetamide, extraction from the herb Echinacea purpurea, caffeic and chlorogenic acids do not have the stated effect. Among the essential oils studied tea tree essential oil has the greatest bacteriostatic and bactericidal activity and exceeds protargol in these indicators. A stronger effect was noted for framycetin sulfate and neomycin sulfate with polymyxin B sulfate. According to the study results tea tree, eucalyptus, lavender and sage essential oils can be recommended for the composition inclusion in nasal preparations as a more “gentle” replacement of antibiotics.
Abstract licence: CC BY
Patel P
2024
Abstract Antibacterial creams come in a wide variety, with varying concentrations, prices, levels of activity, active ingredients, and excipients. Based on their ability to suppress the chosen bacterial strains (S. aureus, E. coli, B. subtilis, P. vulgaris) four different commercial antibacterial creams were evaluated as the most popular ones. There were two types of creams: one with gentamicin sulfate and the other with framycetin sulphate. The combination medicine creams included silver sulfadiazine, miconazole nitrate, neomycin sulfate, and chlorhexidine gluconate. In addition to being commonly utilized due to their antibacterial properties, the chosen bacterial strains are principally responsible for the majority of human illnesses and skin disorders. The study explains the four creams that were utilized, how economical they were, how well they worked against various bacterial strains, and how efficient they were whether applied singly or in combination. It also aids in determining which cream performs the best overall. In the antibacterial experiment, the disk diffusion method was used to use all four of the creams. Out of the four antibacterial creams, the study indicates that gentamicin had the highest efficacy. Among the three drugs that make up cream, gentamicin is the most economical and has the biggest zone of inhibition of all four creams combined. This study improves our knowledge of the best cream while also educating pharma providers regarding the advantages of creams.
Abstract licence: CC BY
Ayush Soni, Sunita Sonartiya, Neelam Patel, et al.
International Journal of Pharmaceutical Sciences and Medicine, 2024
Ferra Olivia Mawu, Grace Kapantow, Hani Lusyana
Indonesia Journal of Biomedical Science, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
199 found
Half-life
Not available
Mechanism
Framycetin binds to specific 30S-subunit proteins and 16S rRNA, four nucleotides…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 861 interactions
Proteins and enzymes this drug interacts with in the body
PMID:10452968 PMID:18799424 PMID:24912431 PMID:28978524
Involved in the AKT signaling cascade .
PMID:24912431
Plays a role in regulation of cell migration, e.g. during wound healing .
PMID:28978524
Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels .
PMID:20228059
Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes .
PMID:11276205
Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development.
In the CNS, could mediate hippocampal-neuron survival (By similarity)
ATC D09AA01
ATC R01AX08
ATC S01AA07
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Framycetin
Additional database identifiers
Drugs Product Database (DPD)
8626
Drugs Product Database (DPD)
8628
ChemSpider
8075
BindingDB
19
PDB
NMY
ZINC
ZINC000071928291
GenBank Gene Database
V00355
GenBank Protein Database
43010
UniProt Accession
RS12_ECOLI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2561
GenAtlas
CXCR4
GeneCards
CXCR4
GenBank Gene Database
L01639
GenBank Protein Database
189314
Guide to Pharmacology
71
UniProt Accession
CXCR4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q4492348), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.